These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33028137)

  • 1. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
    Agirgol S; Çaytemel C; Pilanci KN
    Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
    Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
    Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
    Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
    Yalici-Armagan B; Ayanoglu BT; Demirdag HG
    Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
    [No Abstract]   [Full Text] [Related]  

  • 6. Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients.
    Lee JS; Woo J; Kim TM; Kim N; Keam B; Jo SJ
    Acta Derm Venereol; 2024 Aug; 104():adv40555. PubMed ID: 39192813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
    Amitay-Laish I; David M; Stemmer SM
    Oncologist; 2010; 15(9):1002-8. PubMed ID: 20709888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
    Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.
    Segaert S; Van Cutsem E
    Ann Oncol; 2005 Sep; 16(9):1425-33. PubMed ID: 16012181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis.
    Gorji M; Joseph J; Pavlakis N; Smith SD
    Asia Pac J Clin Oncol; 2022 Dec; 18(6):526-539. PubMed ID: 35352492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
    Chiang TY; Hsu HC; Jane SW; Chen SC
    Support Care Cancer; 2020 Oct; 28(10):4771-4779. PubMed ID: 31974771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report.
    Gürbüz M; Akkuş E; Utkan G
    J Oncol Pharm Pract; 2021 Mar; 27(2):480-484. PubMed ID: 32623964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center.
    Yu Z; Dee EC; Bach DQ; Mostaghimi A; LeBoeuf NR
    JAMA Dermatol; 2020 Oct; 156(10):1079-1085. PubMed ID: 32609305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of risk factors for skin disorders caused by anti-epidermal growth factor receptor antibody drugs and examination of methods for their avoidance.
    Takahashi H; Asaka J; Tairabune T; Ujiie H; Matsuura Y; Nihei S; Kimura T; Chiba T; Kudo K
    J Clin Pharm Ther; 2021 Oct; 46(5):1404-1411. PubMed ID: 34145608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer.
    Bouché O; Ben Abdelghani M; Labourey JL; Triby S; Bensadoun RJ; Jouary T; Des Guetz G
    World J Gastroenterol; 2019 Aug; 25(29):4007-4018. PubMed ID: 31413534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cutaneous side effects of EGFR inhibitors--appearance and management].
    Wollenberg A; Kroth J; Hauschild A; Dirschka T
    Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cutaneous toxicities].
    Matsumoto K; Saida T
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1645-8. PubMed ID: 18931563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients.
    Santiago F; Gonçalo M; Reis JP; Figueiredo A
    An Bras Dermatol; 2011; 86(3):483-90. PubMed ID: 21738965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review.
    Yuan C; Wang B
    J Cosmet Dermatol; 2023 Aug; 22(8):2150-2157. PubMed ID: 36924348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
    Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
    J Dermatolog Treat; 2016; 27(2):148-52. PubMed ID: 26313697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.